Objectives: To determine how infant feeding recommendations can maximize HIVfree survival (HFS) among HIV-exposed, uninfected African infants, balancing risks of breast milk-associated HIV infection with setting-specific risks of illness and death associated with replacement feeding.
Introduction
Breastfeeding is critical to infant health and survival in many resource-limited settings [1] . Breast milk provides optimal nutrition, especially when access to replacement milk is limited; passive transfer of maternal antibody protects against infectious diseases such as diarrhea and pneumonia; and exclusive breastfeeding avoids exposure to water contaminated with enteric pathogens [1] [2] [3] . For HIV-infected mothers, however, breastfeeding also places HIV-uninfected infants at risk of HIV infection. In the absence of antiretroviral drugs for prophylaxis, up to 40% of mother-to-child transmission (MTCT) of HIV worldwide is attributed to breastfeeding [4, 5] . Maternal or infant antiretroviral drugs can markedly reduce breastfeeding-related MTCT, but the risk of HIV transmission is not completely eliminated, and the residual risk remains greatest for women with advanced HIV disease (CD4 þ cell count 350/ml) [6] [7] [8] [9] [10] [11] [12] .
The WHO 2010 and 2013 HIV and Infant Feeding Guidelines address this dilemma facing HIV-infected women and emphasize a goal of infant HIV-free survival (HFS) to simultaneously consider risks of HIV and those of infection-related death [1, 13] . To simplify infant feeding recommendations, the WHO promotes a 'public health approach'. The guidelines recommend the choice at country or program level between avoidance of breastfeeding, suggested where water supplies are safe and infant formula quantity is adequate, and 12 months of breastfeeding with infant or maternal antiretroviral drug prophylaxis (Appendix Table A , http://links.lww.com/ QAD/A531) [1, 13] . However, infant HFS might be maximized by individualized recommendations regarding breastfeeding duration, in which risks of MTCT are balanced against risks of replacement feeding-associated mortality (Appendix Fig. A , http://links.lww.com/ QAD/A531). Such an individualized approach may be difficult to implement in maternal-child health settings. As neither clinical trials nor fully comprehensive cohort data exist to address this question, we used a validated computer simulation model to investigate the duration of breastfeeding that maximizes HFS for HIV-exposed, uninfected infants who live in settings of alternative replacement feeding-associated risk [14, 15] .
Methods

Analytic overview
We used the Cost-Effectiveness of Preventing AIDS Complications (CEPAC)-infant model to simulate HIVexposed, uninfected infants in sub-Saharan Africa [14, 15] . The primary outcome was 24-month HFS, defined as being alive and HIV-uninfected at 24 months after birth. Although prevention of MTCT (PMTCT) regimens are chosen at the program or national level, water safety and the availability of antiretroviral drugs and infant formula may vary, even between patients in a given program. To simulate conditions faced by individual women, we modeled numerous scenarios, reflecting variations in: maternal CD4 þ distribution, antiretroviral drug availability, and the relative risk of mortality among replacement-fed compared to breastfed infants ('RR-RF'), which varied from 1.0 (no increased mortality risk associated with replacement feeding) to 6.0 (e.g. poor water quality, insufficient quantities of replacement milk, or diarrheal outbreaks) [5, 6, [16] [17] [18] [19] [20] [21] .
First, we projected infant 24-month HFS at breastfeeding durations of 0, 3, 6, 9, 12, 18, and 24 months, and identified the breastfeeding duration that maximized projected 24-month HFS for each combination of maternal disease stage, antiretroviral drug availability, and RR-RF value. We termed this the 'individualized approach', because it might allow a provider to counsel a new mother regarding how long she should breastfeed, given information about her CD4 þ cell count, medication use, and the safety and adequacy of the water and replacement milk supply available to her. Second, we compared these results to the projected HFS with 12 months of breastfeeding by all women in the multinational MTCT-Plus cohort (the WHO 'public health approach') [1, 22] .
Modeled population
We assigned HIV-exposed, uninfected infants born in sub-Saharan Africa to one of five categories of maternal CD4 þ and maternal-infant antiretroviral drug availability: maternal CD4 þ 350/ml or less, with no postnatal antiretroviral drugs available; maternal CD4 þ above 350/ ml, with no postnatal antiretroviral drugs available; maternal CD4 þ 350/ml or less, with lifelong maternal postnatal three-drug antiretroviral therapy (ART); maternal CD4 þ above 350/ml, with infant nevirapine throughout breastfeeding; and maternal CD4 þ above 350/ml, with postnatal maternal three-drug antiretroviral drug prophylaxis throughout breastfeeding [13, 23, 24] . These categories reflected a range of MTCT risks under 2006, 2010, and 2013 WHO-recommended regimens for PMTCT. Although 2013 WHO guidelines suggest a CD4 þ threshold of 500/ml or less for initiation of ART in nonpregnant patients, few data are available to model the WHO-recommended 'option A' and 'option B' PMTCT regimens using this threshold [2, 6, [10] [11] [12] [13] 16, [25] [26] [27] [28] [29] [30] [31] [32] [33] . In addition, WHO 2013 guidelines recommend option B or Bþ, in which all pregnant women initiate ART regardless of CD4 þ threshold [13] . Like other investigators, we therefore used a CD4 þ threshold of 350/ml to stratify risks of postnatal HIV transmission [34] .
Model structure
CEPAC-infant model
The CEPAC-infant model is a first-order, Monte Carlo simulation model of infant HIV infection and survival, detailed in the Appendix [14, 15, 35] . For this analysis,
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AIDS 2014, Vol 28 (Suppl 3) infants entered the model at birth and faced monthly risks of three key events: maternal death, after which infants were no longer at risk for HIV infection due to cessation of breastfeeding, but faced higher mortality rates due to maternal orphanhood [36] [37] [38] [39] ; postnatal HIV infection throughout the duration of breastfeeding, stratified by maternal CD4 þ and maternal-infant antiretroviral drug regimen [2, 6, [10] [11] [12] 16, [25] [26] [27] [28] [29] [30] [31] [32] [33] ; and all-cause infant mortality, stratified by age, infant HIV infection status, receipt of ART if infected, and maternal vital status. Baseline rates of infant mortality were applied to breastfed infants [8, 40] ; for replacement-fed infants, these mortality rates were multiplied by published values of the 'RR-RF' multiplier [5, 6, [16] [17] [18] [19] [20] [21] . Model outcomes include true infant HIV and vital status, allowing calculation of cohort HFS at the end of each simulated month.
Breastfeeding type and duration When modelled, breastfeeding duration was 0 months, infants were assumed to initiate replacement feeding immediately after birth. For all other modeled breastfeeding durations (3-24 months), infants were assumed to wean after the last month of breastfeeding. In the base case, breastfeeding in the first 6 months of life was modeled as exclusive breastfeeding, as per WHO guidelines [1, 13] , and breastfeeding after 6 months of age was modeled as complementary feeding, combining breast milk with other solid and liquid foods. We examined the impact of mixed breastfeeding in the first 6 months of life in sensitivity analyses.
Model input parameters
Postnatal transmission risks Postnatal MTCT risks were derived from PMTCT studies among breastfed, African infants, stratified by maternal-infant antiretroviral drug regimen and maternal CD4 þ cell count (Table 1 , section I, http:// links.lww.com/QAD/A531) [2, 6, [10] [11] [12] 16, [25] [26] [27] [28] [29] [30] [31] [32] [33] 41] . We applied these risks from birth through cessation of breastfeeding [4] . In the base case, MTCT risks were the average of published values for each regimen and current maternal CD4 þ cell count. We then varied these using the highest and lowest published MTCT rates for each regimen simultaneously, as a proxy for maternal and infant antiretroviral drug adherence throughout breastfeeding ('highest MTCT risk' and 'lowest MTCT risk' scenarios; Table 1 and Appendix, http://links.lww.com/ QAD/A531) [15] . Infants were assumed to experience no risk of HIV acquisition after breastfeeding stopped.
Mortality rates
Infant mortality rates were from Joint United Nations Programme on HIV/AIDS (UNAIDS) analyses of pooled data for HIV-exposed, uninfected breastfeeding infants in eight African countries, stratified by age (Table  1 , section II, http://links.lww.com/QAD/A531) [8, 40] . In sensitivity analyses, we examined 'low-mortality' (UNAIDS lower 95% confidence limit) and 'highmortality' (UNAIDS upper 95% confidence limit) scenarios. Rates of maternal mortality were projected using the CEPAC-adult model ( 
RR-RF values and duration
We derived values for the RR-RF mortality multiplier from published studies reporting all-cause mortality among HIV-exposed, breastfed and replacement-fed infants (Table 1 , section IV, http://links.lww.com/ QAD/A531) [5, 6, [16] [17] [18] [19] [20] [21] . In the base-case analysis, RR-RF was modeled to apply from initiation of replacement feeding until the end of the simulation (month 24). It is unknown whether the highest risk of mortality from shorter breastfeeding occurs at specific high-vulnerability ages, or instead, for a high-risk period immediately after weaning [3, 6, 20, 42, 43] . We therefore conducted two sensitivity analyses. First, we applied the RR-RF mortality multiplier only until infants reached specific ages (i.e. until 6 or 12 months of age, for infants weaned prior to those ages). Second, we applied the RR-RF mortality multiplier only for specific durations after weaning (i.e. for 1, 3, 6, or 12 months after weaning, regardless of the age at weaning).
Model validation
The CEPAC-infant model has previously been validated against published risks of postnatal infant HIV infection and mortality [14] . We further validated the model for the outcome of HFS, using a published comparison of breastfeeding and maternal ART vs. replacement feeding in Rwanda (Appendix, http://links.lww.com/QAD/ A531) [16] .
Additional sensitivity analyses
Following international modeling recommendations, we conducted extensive univariate and multivariate sensitivity analyses on all key model input parameters, through ranges shown in Table 1 [44, 45] . In addition to the sensitivity analyses outlined for the parameters above, we also varied the impact of maternal mortality on infant mortality (range 1-2-fold increase in infant mortality risk following maternal death) [36] and the proportion of infants who were mixed breastfed in the first 6 months of life (range 0-100%).
Breastfeeding recommendations: individualized vs. public health approach The WHO 2010 HIV and Infant Feeding Guidelines include 16 principles and recommendations, encompassing a range of maternal and infant health-related interventions (Appendix Table A , http://links.lww. com/QAD/A531). Although principles 5 and 6 include counseling, they deliberately focus on 'supporting mothers in their feeding practices' rather than 'a process of decision-making'. Most programs have emphasized principle 3 and recommendation 2, which suggest 12 months of breastfeeding with maternal or infant antiretroviral drug prophylaxis for all HIV-infected women. We termed this the 'public health approach'. To compare the individualized and public health approaches, we simulated a cohort of women and infants similar to the multicountry MTCT-Plus cohort, in which 2741 of 6036 women (45%) had CD4 þ 350/ml or less [22] . We projected 24-month HFS, assuming option B/Bþ (ART throughout breastfeeding; Appendix Table A , http://links.lww.com/QAD/A531) [1] . To reflect a range of settings, we varied both RR-RF (from 1.0-6.0) and the 'uptake' of recommended antiretroviral drugs (proportion of mother-infant pairs receiving and adhering to recommended regimens; range 50-100%). Because the individualized approach may be burdensome to healthcare providers, we modeled two additional scenarios in which providers were unable to give any infant feeding counseling to 25% of mothers under the individualized strategy, for example, leading them to breastfeed for 24 months without antiretroviral drug prophylaxis or to replacement feed from birth (Appendix, http://links.lww.com/QAD/A531) [1, 46] .
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AIDS 2014, Vol 28 (Suppl 3) ART, three-drug antiretroviral therapy; EBF, exclusive breastfeeding (in first 6 months of life, followed by complementary feeding thereafter); m, months; MBF, mixed breastfeeding (in first 6 months of life, followed by complementary feeding thereafter); PMTCT, prevention of mother-to-child HIV transmission. a
The ranges shown for sensitivity analyses are the highest and lowest published values for each regimen. For the 'highest MTCT risk' scenario, we used the upper limit of each range; for the 'lowest MTCT risk' scenario, we used the lower limit. These MTCT ranges may represent a proxy for adherence to maternal and infant antiretroviral drugs in PMTCT trials.
b Mortality rates are stratified by current age in each month of the simulation. The RR-RF value was calculated by dividing cumulative mortality risk (at the greatest duration reported in each study) among replacement-fed infants by cumulative mortality risk among breastfed infants.
Results
Model validation
Model-projected HFS was within 2% of observed HFS for both replacement-fed and breastfed infants, at 30-270 days after birth (Appendix Table B , http://links.lww. com/QAD/A531) [16] .
Base-case results
For all scenarios, projected HFS ranged from a low of 64.7% (RR-RF ¼ 6.0, no breastfeeding, solid circle in Table 2 ) to a high of 93.0% (RR-RF ¼ 1.0, no breastfeeding; dashed circle in Table 2 ). Overall, HFS was inversely related to RR-RF and directly related to maternal CD4 þ and antiretroviral drug availability.
The RR-RF value of 1.0 represented a unique case (Fig. 1 , Table 2 ): HFS was maximized (93.0%) by replacement feeding from birth for all combinations of maternal CD4 þ and antiretroviral drug availability. At RR-RF value of 1.0, any duration of breastfeeding led only to increased MTCT risk, without reduction in replacement feeding-associated mortality. HFS therefore declined steadily with increasing breastfeeding duration, to nadir values ranging from 72.7% (maternal CD4 þ 350/ ml or less, no antiretroviral drugs, solid circle in Table 2 ) to 89.0% (maternal CD4 þ above 350/ml, maternal ART).
For RR-RF values above 1.0, the breastfeeding duration that maximized projected HFS depended on the interaction of maternal CD4 þ , antiretroviral drug availability, and the RR-RF value (Table 2, Fig. 1 ). For example, at the commonly reported RR-RF value of 2.0, HFS ranged from 72.3% (Table 2 , solid circle) to 89.8% (dashed circle) [6, 19, 20, 42] . In the scenario with highest MTCT risk (maternal CD4 þ 350/ml and no antiretroviral drugs) at RR-RF value of 2.0, infant HFS was maximized with 3 months of breastfeeding (87.1%); beyond 3 months of breastfeeding, the risk of HIV infection outweighed the risk of mortality associated with replacement feeding. In maternal CD4
þ / antiretroviral drug scenarios with lower MTCT risks, longer breastfeeding durations were preferred ( Table 2) . As RR-RF value increased beyond 2.0, the mortality reductions associated with breastfeeding became relatively greater than the risks of MTCT, and HFS was maximized with longer breastfeeding durations. At the extreme RR-RF value of 6.0, HFS ranged from 64.7% (solid circle) to 88.8% (dashed circle) and was maximized by breastfeeding durations of 12 months (maternal CD4 þ 350/ml, no antiretroviral drugs; HFS 76.8%), 18 months (CD4 þ >350/mL, no antiretroviral drugs; HFS 85.2%), and 24 months (all other CD4 þ /antiretroviral drug categories; HFS 85.6-88.8%; Table 2 , Fig. 1 ).
Sensitivity analyses
Results of univariate and multivariate sensitivity analyses that led to changes in optimal breastfeeding duration are shown in Table 3 and Appendix Tables C-F (http:// links.lww.com/QAD/A531). The 'lowest MTCT risk' scenario, likely reflecting optimal adherence to maternal or infant antiretroviral drugs, led to longer optimal breastfeeding durations than the base-case analysis, up to 24 months of breastfeeding in most scenarios when RR-RF value was at least 3.0 (Appendix Table C , http:// links.lww.com/QAD/A531). In contrast, most 'highest MTCT risk' scenarios, likely reflecting poorer adherence, favored shorter breastfeeding durations than the base case (Appendix Table D , http://links.lww.com/QAD/A531). When the RR-RF value was applied for more limited time periods than in the base case, HFS was maximized by weaning at earlier ages (Appendix Tables E and F, http:// links.lww.com/QAD/A531). However, if the RR-RF value was applied for 12 months after weaning, the optimal breastfeeding durations were very similar to the base-case results. In addition to these analyses, we also varied all other key model inputs; the optimal breastfeeding duration was relatively insensitive to variations in the proportion of infants mixed breastfed in the first 6 months of life, infant mortality rates, or increased risk of infant mortality following maternal mortality (not shown).
Individualized vs. public health approach
For the MTCT-Plus cohort [22] , assuming guidelineconcordant care with options B/Bþ, projected gains in 24-month infant HFS with the individualized approach compared to the public health approach were only 0.1% if RR-RF value was 2.0, and 0.3% if RR-RF value was 3.0 (Fig. 2a) . Gains in HFS increased to 1.0-1.9% if RR-RF value was 4.0-5.0, and were greatest at the extreme values of RR-RF (2.7% if RR-RF ¼ 1.0, 2.9% if RR-RF ¼ 6.0). If antiretroviral drugs were only available for 50% of mother-infant pairs (Fig. 2b) , gains in HFS with the individualized approach were greatest at the RR-RF value of 1.0 (4.6%), but smaller at RR-RF values of 2.0-6.0 (0.9-1.9%). If the individualized approach rendered healthcare workers unable to provide counseling to 25% of the new mothers, leading them to either breastfeed for 24 months without antiretroviral drugs or to avoid breastfeeding, the individualized approach reduced cohort HFS for select combinations of maternal CD4 þ , antiretroviral drug availability, and RR-RF (Fig. 2c, d ).
Discussion
The model-based analysis has four key findings. First, HFS for HIV-exposed, uninfected infants is maximized by shorter breastfeeding durations if maternal HIV disease is advanced or postnatal antiretroviral drugs are unavailable, and by longer breastfeeding durations in settings where replacement feeding is associated with high infant-child mortality risks. Second, the optimal breastfeeding duration depends substantially on postnatal MTCT risks for each combination of maternal CD4 þ and antiretroviral drug regimen, which are primarily related to antiretroviral drug adherence. Although low adherence to maternal antenatal antiretroviral drug prophylaxis and postnatal ART has been reported, there are limited data about adherence to maternal or infant antiretroviral drug prophylaxis (options A and B) throughout the long durations required by extended breastfeeding [47] [48] [49] . Our base case incorporated average transmission risks observed in PMTCT trials, and we assumed constant transmission risks and adherence throughout breastfeeding [4] . Postnatal adherence may be substantially lower in nontrial settings, and adherence to maternal and infant antiretroviral drugs may wane over time. These conditions are at least partly reflected in our 'highest MTCT risk' scenarios, in which optimal breastfeeding durations are often shorter than the WHO 12-month recommendation, especially if RR-RF value is low (Table 3) . Conversely, if the lowest published MTCT risks are assumed, likely reflecting outstanding adherence to antiretroviral drugs or longer durations of maternal ART prior to delivery [11, 12] , the optimal breastfeeding duration approaches 24 months in most scenarios.
Third, the interaction between postnatal MTCT risk and RR-RF is important. Increases in RR-RF values exert less influence on optimal breastfeeding duration when antiretroviral drugs are not available than when they are available. However, even at moderate RR-RF values, HFS is greater when women breastfeed without antiretroviral drugs than when breastfeeding is avoided altogether, especially for women with CD4 þ above 350/ ml. In most settings with RR-RF value of 1.0, women should not avoid breastfeeding while awaiting access to antiretroviral drugs.
Fourth, these results suggest the possibility of tailoring infant feeding recommendations for individual patients.
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AIDS 2014, Vol 28 (Suppl 3) There are clear challenges to such an 'individualized' approach. First, information about water safety and replacement milk supply in the community may not accurately predict the RR-RF for individual infants. Second, an individualized approach may be too cumbersome for healthcare workers to implement, and previous efforts to individualize infant feeding recommendations have led to confusion about feeding recommendations for both HIV-infected and HIVuninfected women [1, 46, [50] [51] [52] . Our results suggest that the individualized approach could lead to moderate benefits compared to the public health approach, but only when RR-RF value is very low or very high or antiretroviral drug availability is limited; some providers may already be individualizing feeding recommendation in such situations [50, 52] . The individualized approach is likely of minimal benefit at the intermediate values of RR-RF expected in most settings, or as programs scale up the availability of maternal ART under options B/Bþ. Whereas model-based analyses cannot capture all of the challenges of individualization, we find that if the time required to individually counsel some mothers leads other mothers to receive no counseling at all, the individualized approach may actually reduce infant HFS (Fig. 2c, d ).
Individualizing HIV and infant feeding guidelines Ciaranello et al. S293 Projected 24-month HIV-free survival among HIV-exposed, uninfected infants at birth. ART, three-drug antiretroviral therapy; NVP, nevirapine; RR-RF, relative risk of mortality among replacement-fed compared to breastfed infants (see Methods section). a Yellow shading indicates the maximum value of HIV-free survival (HFS) for each unique combination of RR-RF value, maternal CD4 þ cell count and antiretroviral drug availability. Circled values are the high HFS (solid circles) and low HFS (dashed circles) for each value of RR-RF.
b When breastfeeding duration is 0 months, HFS is equivalent for all CD4 þ /antiretroviral drug categories for each value of RR-RF. Because we assume no MTCT risk with replacement feeding from birth, HFS is determined solely by mortality, which depends on RR-RF, but not on maternal CD4 þ or antiretroviral drug availability. c In all scenarios, the RR-RF is not applied to infants who are breastfed for 24 months (weaning occurs at the end of the simulation). For each combination of maternal CD4 þ and antiretroviral drug availability, HFS at breastfeeding durations of 24 months decreases slightly as the RR-RF increases (e.g. with CD4
þ >350 and maternal ART, HFS decreases from 89.0 at RR-RF ¼ 1.0 to 88.8 at RR-RF ¼ 6.0). This occurs because infants necessarily wean if maternal mortality occurs, and the RR-RF then takes effect for the small proportion of infants whose mothers have died. Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
The work confirms and extends the results of prior model-based analyses, which reflected MTCT risk in the absence of maternal-infant antiretroviral drug prophylaxis and identified either 6 months of breastfeeding or replacement feeding from birth as the optimal strategy in most settings [53] [54] [55] [56] . Our analysis additionally incorporates the following: use of postnatal maternal/infant antiretroviral drugs; transmission risks stratified by maternal HIV disease stage; breastfeeding durations from 0 to 24 months (including the WHO-recommended 12-month duration); and explicit variations in RR-RF to reflect a range of settings.
Model-based analyses necessarily simplify complex biologic and operational processes, and it is important to understand key limitations and their impact on model results. Several limitations of our study relate to data regarding mortality rates and RR-RF values, which combine many causes of infant mortality into a single parameter. First, we were unable to identify reports from which we could derive RR-RF values only for HIVexposed, uninfected children, to whom it is applied in CEPAC model. However, the inclusion of children who become HIV-infected, despite varying MTCT and HIVrelated mortality rates, underestimates the protective effect of breastfeeding in each study. Second, we apply the same value of RR-RF for infants of all ages. One WHO report suggests that RR-RF values may decline from ages 0 to 12 months, then remain constant from ages 12 to 23 months, but this analysis excluded HIV-exposed children and African children [43] . Data from Zambia suggest increasing RR-RF values with older age at weaning, whereas other studies have suggested a 'high-risk' period immediately after weaning at any age or following abrupt weaning [3, 6, 20, 42] . We therefore modeled RR-RF without stratification by age or weaning duration, but varied it explicitly through wide ranges (1.0-6.0), and we examined the impact of the ages and duration after weaning at which the RR-RF was applied. Finally, we used UNAIDS-derived child mortality rates, reported
Individualizing HIV and infant feeding guidelines Ciaranello et al. S295 Table 3 . from studies with excellent access to pediatric healthcare [40] . In sensitivity analyses, higher mortality rates that may be more generalizable to nontrial settings did not substantially change optimal breastfeeding durations.
Additional limitations relate to available data about MTCT risks. Our analysis excluded the CD4 þ -independent impact of duration of antenatal antiretroviral drug prophylaxis on postnatal MTCTrisk. Women who initiate ART late in pregnancy or postpartum may not fully suppress HIV RNA in plasma and breast milk by delivery, permitting early breastfeeding MTCT [1, 11] . We also excluded situations in which women continue breastfeeding after antiretroviral drug prophylaxis is stopped, either intentionally or due to medication stock-outs, or stop and then resume breastfeeding (re-lactation), thereby increasing HIV concentration in breast milk [57] . True postnatal risks may approach our 'lowest MTCT risk' scenario if maternal ART is initiated early in pregnancy and if women are supported to adhere to antiretroviral drugs and continuous breastfeeding, and may approach our 'highest MTCT risk' scenario under opposite conditions. We focused this model-based analysis on the outcome of HFS, and thus did not examine other potential impacts of the individualized and public health approaches on maternal-child health services for HIV-infected patients and the general population [46, 50, 51] . Notably, the WHO-recommended outcome of HFS reflects an implicit valuation of infant HIV infection as 'equal' to death [1] . As access to early infant HIV diagnosis and pediatric ART improves, an endpoint of total 2-year survival may better reflect public health goals [58] . Such an endpoint would also incorporate the benefits of breastfeeding for infants already HIV-infected [59] . Analyses that examine strategies to maximize total 2-year survival and incorporate HIV-infected infants [56] will favor longer optimal breastfeeding durations than the current analysis.
In conclusion, over 765 million people live without access to safe drinking water, including 37% of people living in sub-Saharan Africa [60] . Additionally, only 65% of HIVinfected, pregnant women receive ART in sub-Saharan Africa; a smaller percentage receive treatment in South Women not counseled breastfeed for 24m without ARVs
Women not counseled replacement feed from birth 50% access to ARVs 100% access to ARVs (base case) and south-east Asia, the Middle East, and North Africa, and access to therapy during breastfeeding is likely lower still [61] . This confluence of public health challenges underscores the importance of balancing the health risks from unsafe drinking water with those of MTCT transmission of HIV. By using recent data on MTCT risks with modern infant and maternal antiretroviral drug regimens, and by comparing a range of mortality risks from lack of breastfeeding, this analysis provides an updated assessment of the WHO HIV and Infant Feeding Guidelines. Consideration of maternal CD4 þ cell count, antiretroviral drug availability, and local/personal conditions affecting the safety of replacement feeding may allow providers to tailor infant feeding recommendations under very specific circumstances. Compared to current WHO recommendations [1] , this individualized approach is projected to lead to improved infant HFS only in settings where the mortality risks associated with replacement feeding are very low or very high, or where access to antiretroviral drugs for prophylaxis of postnatal HIV transmission remains limited. Our results suggest that the current WHO public health policy is beneficial in most resource-limited settings.
